Invex Therapeutics (ASX:IXC) FCF Yield % : -83.49 (As of May. 27, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Invex Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Invex Therapeutics's Trailing 12-Month Free Cash Flow is A$-5.27 Mil, and Market Cap is A$6.31 Mil. Therefore, Invex Therapeutics's FCF Yield % for today is -83.49%.

The historical rank and industry rank for Invex Therapeutics's FCF Yield % or its related term are showing as below:

ASX:IXC' s FCF Yield % Range Over the Past 10 Years
Min: -128.73 Med: 0 Max: 0
Current: -83.49

ASX:IXC's FCF Yield % is ranked worse than
83.58% of 1553 companies
in the Biotechnology industry
Industry Median: -14.53 vs ASX:IXC: -83.49

Invex Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

Invex Therapeutics FCF Yield % Historical Data

The historical data trend for Invex Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invex Therapeutics FCF Yield % Chart

Invex Therapeutics Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

FCF Yield %

-1.83

-3.54

-9.08

-45.70

Invex Therapeutics Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Yield %	Get a 7-Day Free Trial				-5.10	-10.90	-19.12	-39.31	-76.12

Competitive Comparison of Invex Therapeutics's FCF Yield %

For the Biotechnology subindustry, Invex Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Invex Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Invex Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Invex Therapeutics's FCF Yield % falls into.

Invex Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Invex Therapeutics's FCF Yield % for the fiscal year that ended in Jun. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-6.869	/	15.03076
	=	-45.70%

Invex Therapeutics's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-2.317	*	2	/	6.0874578
	=	-76.12%

Invex Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Invex Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Invex Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Invex Therapeutics (ASX:IXC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Invex Therapeutics Ltd (ASX:IXC) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

38 Rowland Street, Level 1, Subiaco, WA, AUS, 6008

Website

https://www.invextherapeutics.com

Invex Therapeutics Ltd is a biopharmaceutical company, focused on the research and development of Exenatide as a treatment for neurological conditions such as Idiopathic Intracranial Hypertension (IIH), traumatic brain injury, or acute stroke. Its other program under development is Presendin which can be used for disabling headaches and permanent vision loss in females. Geographically, it operates only in Australia.